Frontlight ResearchEarly access
Active, not recruitingPhase 1
Study to Evaluate Investigational Allogeneic Cell Therapy Product hOMSC300 for Treatment of Early to Moderate Stage Multiple System Atrophy (MSA)
Key facts
- Who runs it
- Cytora Ltd.
- Where
- Israel1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Active, not recruiting
- Phase
- Phase 1
- People taking part
- 10 people enrolled
- Started
- 7 Nov 2022
- Ended
- 19 Feb 2026
- Type of study
- Interventional, 2 groups
- Treatments tested
- hOMSC300
- Record updated
- 29 January 2025
Who can take part
- Age
- 50 years to 80 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 10 criteriaShow less
Who can take part
- Patient was diagnosed with probable MSA-C (cerebellar) or MSA-P (parkinsonian) variant within 60 months of symptom onset (excluding impotence)
- Subject can ambulate without the assistance of another person, defined as the ability to take at least 10 steps. Use of assistive devices is allowed
- Patient cognitive state permits him to sign informed consent, according to the PI's clinical judgement, and MoCA >= 24
Who cannot take part
- Participants with a clinically significant or unstable medical or surgical condition that, in the opinion of the investigator, might preclude safe completion of the treatment or affect the treatment outcome
- Patients with thrombocytopenia, other bleeding diathesis or taking anticoagulant therapy (not including Aspirin up to 100mg per day)
- Patients with known hypersensitivities to Plasmalyte, Gadolinium, Penicillin, and with general hypersensitivity to antibiotics
- Patients who fulfill the criteria of Parkinson's Disease
- History of electroconvulsive therapy
- History of brain surgery
- Pregnant women and women before menopause
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
Purpose of this phase 1 study is to assess the safety of intrathecal administration of allogeneic human oral mucosa stem cells (hOMSCs) in patients suffering from early to moderate stage Multiple System Atrophy (MSA)
The 2 groups in the trial
- Low dose hOMSC300Treatment being tested
Single IT administration of low dose hOMSC300
Treatment: hOMSC300
- High dose hOMSC300Treatment being tested
Single IT administration of high dose hOMSC300
Treatment: hOMSC300
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Phase 1 Open-Label Study for Treatment of Early to Moderate Stage Multiple System Atrophy Patients With the Investigational Allogeneic Cell Therapy Product, hOMSC300
- Record updated
- 29 January 2025